Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today […]

FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212 CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written […]

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” […]

Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 CALABASAS, Calif., […]

CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming […]

CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including […]

Insider buying indicates management’s conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout – expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study – within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies […]

CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and […]

CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company’s accounting, financial reporting, […]

CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company’s novel oral bio-conjugated therapy and […]